A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Conditions
- Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)Idiopathic Inflammatory Myositis (IIM)Systemic Sclerosis (SSc)Systemic Lupus Erythematosus (SLE)
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 244
- Registration Number
- NCT06308978
- Locations
- 🇺🇸
University of California Irvine, Irvine, California, United States
🇺🇸Children's Hospital Los Angeles Division Of Rheumatology, Los Angeles, California, United States
🇺🇸University of Minnesota Medical School, Minneapolis, Minnesota, United States
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 351
- Registration Number
- NCT06241456
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Yale New Haven Hospital - Yale Cancer Center, New Haven, Connecticut, United States
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
- Conditions
- Relapsed/Refractory B-Cell Lymphoma
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 166
- Registration Number
- NCT05950334
- Locations
- 🇺🇸
Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
- Conditions
- Diffuse Large B Cell LymphomaTransformed Indolent Non-Hodgkin's LymphomaFollicular LymphomaMantle Cell LymphomaMarginal Zone Lymphoma
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Fate Therapeutics
- Registration Number
- NCT05934097
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
- Conditions
- Head and Neck CancerOvarian CancerPancreatic CancerNon Small Cell Lung CancerColorectal CancerGastroEsophageal CancerBreast Cancer
- Interventions
- Combination Product: AvelumabCombination Product: PembrolizumabCombination Product: TrastuzumabCombination Product: CetuximabCombination Product: AmivantamabCombination Product: NivolumabCombination Product: Atezolizumab
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 5
- Registration Number
- NCT05395052
- Locations
- 🇺🇸
Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸UCLA Division of Hematology-Oncology, Los Angeles, California, United States
FT576 in Subjects With Multiple Myeloma
- Conditions
- Multiple MyelomaMyeloma
- Interventions
- Drug: FT576 (Allogenic CAR NK cells with BCMA expression)
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 31
- Registration Number
- NCT05182073
- Locations
- 🇺🇸
Texas Oncology-Medical City Dallas, Dallas, Texas, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸Virginia Oncology Associates, Norfolk, Virginia, United States
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
- Conditions
- Solid Tumor, Adult
- Interventions
- Combination Product: Monoclonal antibody - Dose EscalationCombination Product: Monoclonal antibody - Dose Expansion
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 16
- Registration Number
- NCT05069935
- Locations
- 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
FT819 in Subjects With B-cell Malignancies
- Conditions
- Chronic Lymphocytic LeukemiaLymphoma, B-CellPrecursor B-Cell Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 54
- Registration Number
- NCT04629729
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
FT538 in Subjects With Advanced Hematologic Malignancies
- Conditions
- AML, AdultAcute Myeloid LeukemiaMultiple MyelomaMyeloma
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 42
- Registration Number
- NCT04614636
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
- Conditions
- Solid Tumor, Adult
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT04551885
- Locations
- 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Hackensack University Medical Center/John Theurer Cancer Center, Hackensack, New Jersey, United States